All Companies articles – Page 12
-
ArticleWhy DNA Damage Response deserves renewed focus in cancer therapy
As cancer therapies evolve, a critical opportunity is emerging in the form of DNA Damage Response (DDR) research. With breakthroughs in genomics, drug delivery and AI, DDR pathways are set to overcome resistance and alter treatment strategies. Find out why now is the perfect moment to refocus on DDR, and ...
-
ArticleThe evolution of AI in drug discovery: learning from history's mistakes (Part 2)
In this second part of a two-part series, we continue Sujeegar Jeevanandam’s exploration of the future of AI in drug discovery. We share his vision for transformative AI applications, such as simulating human pharmacokinetics and pharmacodynamics, and offer strategic recommendations for biotechs looking to adopt AI.
-
ReportBeyond the Lab: Artificial Intelligence
Download our latest report to discover how AI is transforming drug discovery, accelerating treatments and driving personalised care.
-
ArticleAbelacimab: the next frontier in safer anticoagulation therapy
Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.
-
NewsFairJourney Biologics acquires Charles River’s South San Francisco facility
FairJourney Biologics S.A., a global leader in antibody discovery and optimisation, has announced its acquisition of Charles River Laboratories’ South San Francisco site.
-
ArticleFrom Yale to healthcare leader: Dr Shika Pappoe’s impact on kidney care
Dr Shika Pappoe’s journey from Yale and Harvard to transforming kidney care highlights how combining clinical expertise with innovation can reshape healthcare. Read on for her insights on overcoming challenges and driving change in STEM and patient care.
-
ArticleThe future of mental health treatment: Zelquistinel's role
Learn about zelquistinel, an innovative NMDA receptor modulator that is transforming treatment possibilities through a novel approach to synaptic plasticity. This breakthrough drug offers new insights into early drug discovery and the future of neuropsychiatric treatment.
-
NewsFirst AI-designed drug, Rentosertib, officially named by USAN
Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
-
ArticleThe evolution of AI in drug discovery: learning from history's mistakes (Part 1)
AI is transforming drug discovery, but its adoption mirrors past technological shifts in the industry. In this first part of a two-part series, we reveal Sujeegar Jeevanandam’s observations of the parallels between AI and the electronic lab notebook revolution, highlighting key challenges, lessons learned, and what the future holds for ...
-
ArticleNavigating the AI revolution: a roadmap for pharma's future
AI-driven drug development, powered by advanced models and expanding data access, is becoming a reality. Learn why navigating regulatory hurdles and mastering biology’s inherent complexities are crucial to fully unlocking its potential.
-
NewsAWS and ElevateBio join forces to advance gene editing
ElevateBio is teaming up with Amazon Web Services (AWS) to advance CRISPR gene editing using AI and cloud computing. This collaboration aims to accelerate drug discovery for genetic diseases, making next-generation therapies more efficient and accessible.
-
ArticleRefining and targeting exatecan with ADC technology
DTR speaks with Dr Patrick van Berkel at ADC Therapeutics to discuss how the company is transforming exatecan delivery to achieve better health outcomes.
-
ArticleShattering the glass ceiling: empowering women and girls in STEM
On International Women’s Day, Assistant Professor Vasiliki E Kalodimou calls for greater commitment to closing the gender gap in STEM. Highlighting the need for gender-neutral education, stronger female representation and actionable strategies to break the glass ceiling, Kalodimou wants women’s participation in innovation to become the norm, not the exception.
-
ArticleEmpowering women in STEM: Navigating CMC regulatory affairs
Discover how a leader in CMC regulatory affairs is transforming drug development and inspiring the next generation of scientists.
-
NewsGoogle’s AI co-scientist accelerates drug development
Google has introduced an AI-powered 'co-scientist' designed to accelerate biomedical research and drug discovery by generating scientific hypotheses and identifying novel therapeutic targets.
-
ArticleHope for ALS and inflammatory diseases: Cellenkos' CRANE technology breakthrough
Cellenkos' CRANE technology, led by Dr Simrit Parmar, harnesses regulatory T cells to precisely target and treat inflammatory diseases. This innovative approach offers hope for conditions like aplastic anaemia, myelofibrosis, and ALS.
-
ArticleThe future of cell therapy: scaling production for global reach
Scaling up cell therapy is no easy feat. PluriCDMO's Andy Lewin reveals the critical factors for success and how they are helping companies bring life-saving therapies to market.
-
ArticleObesity care gets personalised: tailoring therapies with Phenomix
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
-
ArticleNew therapy shows promise in strengthening CAR-T responses
CAR-T therapy has shown effectiveness in cancer treatment, but relapse often occurs due to limited cell persistence. New strategies aim to improve CAR T-cell durability for longer lasting remission.
-
ArticleEmpowering women in STEM: championing change in genetics
An advocate for genetic medicines and the enormous potential they hold, Leah Sabin at Regeneron Genetic Medicines reveals how passion and curiosity can forge the path to a rewarding career in STEM.